Biotech Currents

Biotech Currents

Home
Notes
Perspectives
BioCurrents Updates
Catalyst Table
Schedule
Archive
About
Clinical trial data from Ascendis (ASND), Tourmaline (TRML) push stocks higher
Data-driven rallies highlight potential in rare disease and cardiovascular care
 • 
Bill Langbein
aTyr Pharma's (ATYR) efzofitimod aims to get in front of pulmonary sarcoidosis, lung disease
Assigning a 62.5% overall probability aTyr Pharma will report positive topline data from a phase III trial testing its drug efzofitimod to treat…
 • 
Bill Langbein
1
IDEAYA's (IDYA) darovasertib to address uveal melanoma at various stages of disease
Assigning a 71.1% overall probability IDEAYA will report positive updates from the phase II trial.
 • 
Bill Langbein
The Friday Biotech Perspective #41
A personal vaccine journey and … the Makary-Prasad-RFK Jr. guidance
 • 
Bill Langbein

May 2025

ORR from Merus N.V.’s (NASDAQ:MRUS) H&N cancer drug triggers stock surge
The interim data from 43 evaluable patients revealed a 63% overall response rate
 • 
Bill Langbein
MoonLake's (MLTX) phase III data in Vela trials could kickstart skin disease franchise
Assigning a 68.2% overall probability MoonLake will report positive data from the Vela trials.
 • 
Bill Langbein
Data from Merus N.V.’s (MRUS) petosemtamab may be game changer in Head & Neck cancer
Assigning a 69.2% overall probability updated data from Merus will be significantly positive.
 • 
Bill Langbein
Portfolio Update: The floor plan takes shape for the Trump-RFK Biopharma agenda
Good news first.
 • 
Bill Langbein
1
New Imaging Agent Targets Kidney Cancer With FDA Decision Looming
Assigning a 69.4% overall probability the FDA will sign off on it!
 • 
Bill Langbein

April 2025

March 2025

© 2025 Bill Langbein
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture